The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has cleared a new manufacturing facility for Moderna’s COVID-19 vaccine located in Monts, France.

The plant is owned by Recipharm, a Swedish contract development and manufacturing organization, which will produce the vaccine finished product.

The committee also provided a positive recommendation for several additional Moderna vaccine batch-control and testing sites, including approving two U.S. centers — a Moderna plant in Norwood, Mass., and a Lonza facility in Portsmouth, N.H.

The CHMP recommendation, which does not require a European Commission authorization, will enable the production of an extra “one to two million vials” of vaccine for the EU market each month, the committee said.